Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187055 · ClinicalTrials.gov registry record · Phase 4
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,152
- Enrollment target
NCT02187055 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 1,152 participants.
The verdict
NCT02187055, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,152 participants
- Enrollment target
Study Summary
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. To evaluate the safety and tolerability of tofacitinib and adalimumab. To evaluate the safety of the zoster vaccine given prior to the initiation of tofacitinb or adalimumab.
Interventions
- DRUG Tofacitinib with methotrexate
- DRUG Tofacitinib without methotrexate
- BIOLOGICAL Adalimumab with methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,152 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02187055
The ClinicalTrials.gov registry entry for NCT02187055 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tofacitinib with methotrexate is the first listed.
NCT02187055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02187055 about?
NCT02187055 is a clinical study titled "An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate". To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. To e...
What is the current status of trial NCT02187055?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,152 participants. The study started on 2014-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02187055?
The interventions under investigation include: Tofacitinib with methotrexate (DRUG), Tofacitinib without methotrexate (DRUG), Adalimumab with methotrexate (BIOLOGICAL).
Who is sponsoring clinical trial NCT02187055?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.